From the Cradle to the Clinic: VEGF in Developmental, Physiological, and Pathological Angiogenesis

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 69, Issue 4, 2003, Pages 363-374

  Harry, Lorraine E ^a   Paleolog, Ewa M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BONE DEVELOPMENT; FRACTURE HEALING; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ARTHRITIS, RHEUMATOID; FRACTURE HEALING; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0346655231     PISSN: 1542975X     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrc.10024     Document Type: Review

References (98)

1. Afuwape A, Feldmann M, Paleolog E. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 23:1950-1960.
2. Akeno N, Robins J, Zhang M, et al. 2002. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. Endocrinology 143:420-425.
3. Anderson GI, Richards RR, Paitich B, et al. 1991. Soft-tissue blood flow after segmental osteotomy of the canine tibia. Ann Plast Surg 27:49-55.
4. Ballara SC, Taylor PC, Reusch P, et al. 2001. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44:2055-2064.
5. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. 1999. Growth factor regulation of fracture repair. J Bone Miner Res 14:1805-1815.
6. Berse B, Hunt JA, Diegel RJ, et al. 1999. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 115:176-182.
7. Bolander ME. 1992. Regulation of fracture repair by growth factors. Proc Soc Exp Biol Med 200:165-170.
8. Bouletreau PJ, Warren SM, Spector JA, et al. 2002. Factors in the fracture microenvironment induce primary osteoblast angiogenic cytokine production. Plast Reconstr Surg 110:139-148.
9. Breier G. 2000. Angiogenesis in embryonic development-a review. Placenta 21(suppl A):S11-S15.
10. Breier G, Clauss M, Risau W. 1995. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 204:228-239.
11. Brown RA, Weiss JB, Tomlinson IW, et al. 1980. Angiogenic factor from synovial fluid resembling that from tumours. Lancet 1:682-685.
12. Byrd HS, Cierny G 3rd, Tebbetts JB. 1981. The management of open tibial fractures with associated soft-tissue loss: external pin fixation with early flap coverage. Plast Reconstr Surg 68:73-82.
13. Calderon W, Chang N, Mathes SJ. 1986. Comparison of the effect of bacterial inoculation in musculocutaneous and fasciocutaneous flaps. Plast Reconstr Surg 77:785-794.
14. Cao R, Wu HL, Veitonmaki N, et al. 1999. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci U S A 96:5728-5733.
15. Carmeliet P, Ferreira V, Breier G, et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439.
16. Carmeliet P, Ng YS, Nuyens D, et al. 1999. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5:495-502.
17. Carmeliet P. 2003. Angiogenesis in health and disease. Nat Med 9:653-660.
18. Caudle RJ, Stern PJ. 1987. Severe open fractures of the tibia. J Bone Joint Surg Am 69:801-807.
19. Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. 2001. Effect of human recombinant vascular endothelial growth factor 165 on progression of atherosclerotic plaque. J Am Coll Cardiol 37:2126-2130.
20. Chang N, Mathes SJ. 1982. Comparison of the effect of bacterial inoculation in musculocutaneous and random-pattern flaps. Plast Reconstr Surg 70:1-10.
21. Clauss M, Gerlach M, Gerlach H, et al. 1990. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545.
22. Compernolle V, Brusselmans K, Acker T, et al. 2002. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8:702-710.
23. de Bandt M, Grossin M, Weber AJ, et al. 2000. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 43:2056-2063.
24. Deckers MM, van Bezooijen RL, van der Horst G, et al. 2002. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143:1545-1553.
25. Drake CJ. 2003. Embryonic and adult vasculogenesis. Birth Defects Res Part C Embryo Today 69:73-82.
26. Erdmann NW, Court-Brown CM, Quaba AA. 1997. A five year review of islanded distally based fasciocutaneous flaps on the lower limb. Br J Plast Surg 50:421-427.
27. Fava RA, Olsen NJ, Spencer-Green G, et al. 1994. Vascular permeability factor/ endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341-346.
28. Feldmann M, Maini RN. 2001. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163-196.
29. Ferguson C, Alpern E, Miclau T, Helms JA. 1999. Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev 87:57-66.
30. Ferrara N, Carver-Moore K, Chen H, et al. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442.
31. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669-676.
32. Firestein GS. 1999. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 103:3-4.
33. Fong GH, Rossant J, Gertsenstein M, Breitman ML. 1995. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70.
34. Forsythe JA, Jiang BH, Iyer NV, et al. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613.
35. Gerber HP, Vu TH, Ryan AM, et al. 1999. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628.
36. Gerber HP, Ferrara N. 2000. Angiogenesis and bone growth. Trends Cardiovasc Med 10:223-228.
37. Glowacki J. 1998. Angiogenesis in fracture repair. Clin Orthop 355:S82-S89.
38. Godina M. 1986. Early microsurgical reconstruction of complex trauma of the extremities. Plast Reconstr Surg 78:285-292.
39. Gopal S, Majumder S, Batchelor AG, et al. 2000. Fix and flap: the radical orthopaedic and plastic treatment of severe open fractures of the tibia. J Bone Joint Surg Br 82:959-966.
40. Hallock GG. 2000. Utility of both muscle and fascia flaps in severe lower extremity trauma. J Trauma 48:913-917.
41. Hattori K, Dias S, Heissig B, et al. 2001. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193:1005-1014.
42. Hausman MR, Schaffler MB, Majeska RJ. 2001. Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 29:560-564.
43. Holden CE. 1972. The role of blood supply to soft tissue in the healing of diaphyseal fractures. An experimental study. J Bone Joint Surg Am 54:993-1000.
44. Hollander AP, Corke KP, Freemont AJ, Lewis CE. 2001. Expression of hypoxia-inducible factor lalpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 44:1540-1544.
45. Horner A, Bord S, Kelsall AW, et al. 2001. Tie2 ligands angiopoietin-1 and angiopoietin-2 are coexpressed with vascular endothelial cell growth factor in growing human bone. Bone 28:65-71.
46. Jaakkola P, Mole DR, Tian YM, et al. 2001. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472.
47. Jain RK. 2003. Molecular regulation of vessel maturation. Nat Med 9:685-693.
48. Jawed S, Gaffney K, Blake DR. 1997. Intra-articular pressure profile of the knee joint in a spectrum of inflammatory arthropathies. Ann Rheum Dis 56:686-689.
49. Khodaparast O, Coberly DM, Mathey J, et al. 2003. Effect of a transpositional muscle flap on VEGF mRNA expression in a canine fracture model. Plast Reconstr Surg 112:171-176.
50. Kim HH, Lee SE, Chung WJ, et al. 2002. Stabilization of hypoxia-inducible factor-1alpha is involved in the hypoxic stimuli-induced expression of vascular endothelial growth factor in osteoblastic cells. Cytokine 17:14-27.
51. Kim II, Moon S, Kim S, et al. 2001. VEGF stimulates expression of ICAM-1, VCAM-1 and E-selectin through nuclear factor-kappaB activation in endothelial cells. J Biol Chem 276:7614-7620.
52. Kiriakidis S, Andreakos E, Monaco C, et al. 2003. VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase defective form of the IκB kinase 2. J Cell Sci 116:665-674.
53. Koch AE, Harlow LA, Haines GK, et al. 1994. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:4149-4156.
54. Koch AE. 2000. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 59(suppl 1): i65-i71.
55. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. 2000. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105:71-77.
56. Lu J, Kasama T, Kobayashi K, et al. 2000. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 164:5922-5927.
57. Lund-Olesen K. 1970. Oxygen tension in synovial fluids. Arthritis Rheum 13:769-776.
58. Luttun A, Tjwa M, Moons L, et al. 2002. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8:831-840.
59. Maes C, Carmeliet P, Moermans K, et al. 2002. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 111:61-73.
60. Mandracchia VJ, Nelson SC, Barp EA. 2001. Current concepts of bone healing. Clin Podiatr Med Surg 18:55-77.
61. Marumo T, Schini-Kerth VB, Busse R. 1999. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 48:1131-1137.
62. Millauer B, Wizigmann-Voos S, Schnurch H, et al. 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846.
63. Miotla J, Maciewicz R, Kendrew J, et al. 2000. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 80:1195-1205.
64. Mori S, Yoshikawa H, Hashimoto J, et al. 1998. Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2. Bone 22:99-105.
65. Murohara T, Ikeda H, Duan J, et al. 2000. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 105:1527-1536.
66. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 13:9-22.
67. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. 1995. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 166:196-206.
68. O'Toole G, MacKenzie D, Lindeman R, et al. 2002. Vascular endothelial growth factor gene therapy in ischaemic rat skin flaps. Br J Plast Surg 55:55-58.
69. Paleolog EM, Young S, Stark AC, et al. 1998. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum 41:1258-1265.
70. Paleolog EM. 2002. Angiogenesis in rheumatoid arthritis. In: Feldmann M, Nagase H, Saklatvala J, Walport M, editors. Arthritis research supplement, the scientific basis of rheumatology. Clinical Publishing Services, Oxford, UK. pp. S81-S90.
71. Peng H, Wright V, Usas A, et al. 2002. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110:751-759.
72. Pertovaara L, Kaipainen A, Mustonen T, et al. 1994. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269:6271-6274.
73. Peters KG, De Vries C, Williams LT. 1993. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci U S A 90:8915-8919.
74. Pollak AN, McCarthy ML, Burgess AR. 2000. Short-term wound complications after application of flaps for coverage of traumatic soft-tissue defects about the tibia. The Lower Extremity Assessment Project (LEAP) Study Group. J Bone Joint Surg Am 82A:1681-1691.
75. Pufe T, Wildemann B, Petersen W, et al. 2002. Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing: a study in the rat. Cell Tissue Res 309:387-392.
76. Rhinelander FW. 1968. The normal microcirculation of diaphyseal cortex and its response to fracture. J Bone Joint Surg Am 50:784-800.
77. Richards RR, Schemitsch EH. 1989. Effect of muscle flap coverage on bone blood flow following devascularization of a segment of tibia: an experimental investigation in the dog. J Orthop Res 7:550-558.
78. Rooney M, Condell D, Quinlan W, et al. 1988. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31:956-963.
79. Saadeh PB, Mehrara BJ, Steinbrech DS, et al. 2000. Mechanisms of fibroblast growth factor-2 modulation of vascular endothelial growth factor expression by osteoblastic cells. Endocrinology 141:2075-2083.
80. Semenza GL. 2001. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107:1-3.
81. Senger DR, Galli SJ, Dvorak AM, et al. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
82. Shalaby F, Rossant J, Yamaguchi TP, et al. 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66.
83. Shima DT, Deutsch U, D'Amore PA. 1995. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 370:203-208.
84. Shweiki D, Itin A, Soffer D, Keshet E. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845.
85. Sone H, Kawakami Y, Sakauchi M, et al. 2001. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 281:562-568.
86. Street J, Bao M, deGuzman L, et al. 2002. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 99:9656-9661.
87. Street JT, Wang JH, Wu QD, et al. 2001. The angiogenic response to skeletal injury is preserved in the elderly. J Orthop Res 19:1057-1066.
88. Sumariwalla PF, Cao Y, Wu HL, et al. 2003. The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 5:R32-R39.
89. Suri C, Jones PF, Patan S, et al. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180.
90. Tarkka T, Sipola A, Jamsa T, et al. 2003. Adenoviral VEGF-A gene transfer induces angiogenesis and promotes bone formation in healing osseous tissues. J Gene Med 5:560-566.
91. Tatsuyama K, Maezawa Y, Baba H, et al. 2000. Expression of various growth factors for cell proliferation and cytodifferentiation during fracture repair of bone. Eur J Histochem 44:269-278.
92. Tokuda H, Kozawa O, Miwa M, Uematsu T. 2001. p38 mitogen-activated protein (MAP) kinase but not p44/p42 MAP kinase is involved in prostaglandin E1-induced vascular endothelial growth factor synthesis in osteoblasts. J Endocrinol 170:629-638.
93. Tran J, Rak J, Sheehan C, et al. 1999. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264:781-788.
94. Walsh DA, Wade M, Mapp PI, Blake DR. 1998. Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol 152:691-702.
95. Whiteside LA, Ogata K, Lesker P, Reynolds FC. 1978. The acute effects of periosteal stripping and medullary reaming on regional bone blood flow. Clin Orthop 131:266-272.
96. Yamamoto T, Kozawa O, Tanabe K, et al. 2001. Involvement of p38 MAP kinase in TGF-beta-stimulated VEGF synthesis in aortic smooth muscle cells. J Cell Biochem 82:591-598.
97. Zachary I. 2001. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280:C1375-C1386.
98. Zelzer E, McLean W, Ng YS, et al. 2002. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 129:1893-1904.